A 12-page Executive Summary offering summary highlights for 22 Accountable Care Organizations and ACO solutions companies regarding their successes during the most recent MSSP performance year.
The 10 Most Expensive U.S. Prescription Drugs
- Myalept (Amryt Pharma $71
- 306)
- Ravicti (Horizon Therapeutics $55
- 341)
- Mavenclad (EMD Serono
- Inc. $53
- 730)
- Actimmune (Horizon Therapeutics $52
- 777)
- Oxervate (Dompé $48
- 498)
- Takhzyro (Takeda $45
- 464)
- Daraprim (Vyera Pharmaceuticals $45
- 000)
- Juxtapid (Amryt Pharma $44
- 714)
- Cinryze (Takeda $44
- 141)
- Chenodal (Retrophin
- Inc $42
- 570)
Source: Source: GoodRx: The 20 Most Expensive Drugs in the U.S. - https://www.goodrx.com/blog/20-most-expensive-drugs-in-the-usa/
ACO Performance Case Studies
*By signing up for this offer you agree to receive the Accountable Care bulletin and the HealthExecWire news release bulletin.
Accountable Care
Offerings
Value-Based Payments
Offerings
Analytics
Offerings
Population Health
Offerings
Payers & Providers
Offerings